Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Powell Discusses the Next Steps for CPI-613

July 25th 2013

Bayard L. Powell, MD, the Director-At-Large and a Professor in Hematology & Oncology at the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses the next steps for CPI-613 in hematologic malignancies.

Potential Druggable Targets Identified in Acute Myeloid Leukemia

July 18th 2013

Acute myeloid leukemia is potentially driven by at least one genetic mutation in nearly all cases, with a complex interaction of multiple genetic events contributing to the development of the disease

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10th 2013

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Dr. Brentjens on Treatment With CAR-Modified T Cells

July 1st 2013

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)â€“modified T cells.

Dr. Bollard on the Treatment of EBV-Positive Lymphoma

June 21st 2013

Catherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.

Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer Patient

June 20th 2013

Oncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.

Phase II Data Continue to Back Use of Ibrutinib in CLL

June 19th 2013

Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naÃ¯ve and relapsed/refractory patients with chronic lymphocytic leukemia in an ongoing phase II study.

Dr. Goede on the Results from the Phase III CLL11 Trial

June 19th 2013

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Dr. Fowler on the Mechanism of Action of T-rapa Cells

June 18th 2013

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

Dr. Powell Discusses CPI-613 in Hematologic Malignancies

June 11th 2013

Bayard L. Powell, MD, from the Wake Forest Baptist Medical Center Comprehensive Cancer Center, discusses a phase I study that explored the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

June 10th 2013

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

Dr. Goy on Lenalidomide for Mantle Cell Lymphoma

June 10th 2013

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).

FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma

June 5th 2013

The immunomodulatory agent lenalidomide is now approved by the FDA to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

Dr. Zaks on Patient-Reported Symptom Assessments

May 24th 2013

Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, discusses patient-reported symptom assessment in the phase III JAKARTA trial of SAR302503 for myelofibrosis.

Dr. Erba on Curative Therapy for Acute Myeloid Leukemia

May 22nd 2013

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses treating a patient with acute myeloid leukemia with curative intent.

Pfizer Discontinues Late-Stage Trial of Inotuzumab Ozogamicin

May 21st 2013

A late-stage trial investigating inotuzumab ozogamicin as a treatment for patients with aggressive non-Hodgkin lymphoma has been halted after interim data showed the agent was unlikely to improve survival.

Study Seeks to Eliminate Clinical Barriers to Bone Marrow Transplants

May 21st 2013

Paul V. O'Donnell, MD, PhD, from the Seattle Cancer Care Alliance, discusses a study examining alternative donor transplant methods for patients with hematologic malignancies.

Dr. Cheson on the Lymphoma Research Foundation

May 16th 2013

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the Lymphoma Research Foundation.

New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia

May 15th 2013

The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.

Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma

May 15th 2013

Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.